Skip to main content
PMC home page
PLOS ONE logoLink to PLOS ONE
. 2019 Apr 23;14(4):e0216175. doi: 10.1371/journal.pone.0216175

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer

Sherene Loi, Stefan Michiels, Jose Baselga, John M S Bartlett, Sandeep K Singhal, Vicky S Sabine, Andrew H Sims, Tarek Sahmoud, J Michael Dixon, Martine J Piccart, Christos Sotiriou
PMCID: PMC6478332  PMID: 31013327

The following information is missing from the Competing Interests statement: JB is a consultant to Novartis, Roche, Merck, Sanofi-Aventis, Verastem, Bayer, Chugai, Exelixis, Onyx and Constellation.

Reference

  • 1.Loi S, Michiels S, Baselga J, Bartlett JMS, Singhal SK, Sabine VS, et al. (2013) PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer. PLoS ONE 8(1): e53292 10.1371/journal.pone.0053292 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES